Johnson & Johnson To Buy Drugmaker Intra-Cellular For $14.6 Billion
Johnson & Johnson (JNJ) has announced that it plans to acquire drugmaker Intra-Cellular Therapies (ITCI), which specializes in neurological treatments, for $14.6 billion U.S. Johnson & Johnson will buy all of Intra-Cellular’s shares for $132 apiece, representing a nearly 40% premium to their closing price on Jan. 10. The deal is … Read more